A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma

Trial Profile

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Erlotinib (Primary) ; Capecitabine; Fluorouracil; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Primary endpoint of overall survival (phase II portion) has not been met, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Results of phase II part of this study (n= 336) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 11 May 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2011-000618-20).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top